Nexalin Technology Announces Two Clinical Abstracts Accepted for 2026 NYC Neuromodulation Conference
Summary
Nexalin Technology announced that two clinical abstracts evaluating its proprietary DIFS 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The abstracts, based on the company's recently completed University of Sao Paulo trial, will showcase preliminary results across anxiety, depression, insomnia, and quality of life outcomes, including the 77.8 percent anxiety response rate and durable benefits maintained at 8-week follow-up.
Why it matters
Acceptance at a premier neuromodulation scientific conference provides important third-party validation and exposure to a highly relevant audience of clinicians and researchers. These presentations will help differentiate Nexalin's frequency-based approach from conventional neurostimulation devices and support the company's broader clinical, regulatory, and commercial strategy as it prepares for global commercial initiatives.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial